Evidence map›Paper›PMID 34804219›Full record

ReviewTherapeutic advances in medical oncology2021

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer.

Barbara Melosky, Parneet Cheema, Rosalyn A Juergens, Natasha B Leighl, Geoffrey Liu, Paul Wheatley-Price, Adrian Sacher, Stephanie Snow, Ming-Sound Tsao, Deanna McLeod and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in medical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Barbara MeloskyMedical Oncology, BC Cancer Agency-Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada.ORCID https://orcid.org/0000-0003-2865-659X
Parneet CheemaWilliam Osler Health System, Brampton, ON, Canada.
Rosalyn A JuergensJuravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
Natasha B LeighlPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Geoffrey LiuPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Paul Wheatley-PriceOttawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
Adrian SacherPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Stephanie SnowQEII Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.
Ming-Sound TsaoPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Deanna McLeodKaleidoscope Strategic Inc., Toronto, ON, Canada.
Quincy ChuCross Cancer Institute, University of Alberta, Edmonton, AB, Canada.ORCID https://orcid.org/0000-0003-4814-3126
University of Toronto · CABC Cancer Agency · CADalhousie University · CAJuravinski Cancer Centre · CAUniversity Health Network · CAUniversity of Alberta · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdjuvant platinum-based chemotherapy is standard of care for patients with resected stage IIA/B or IIIA NSCLC. Overall survival is suboptimal due to the high metastatic potential of early-stage NSCLC and there is substantial clinical need for additional efficacious adjuvant treatment options.

methodsPubMed (all time to 4 February 2021) and related conference databases were searched using the key search terms 'NSCLC' AND 'Adjuvant' AND 'EGFR inhibitor' OR respective aliases.

resultsThe literature search identified five adjuvant phase III trials of EGFR inhibitors in early NSCLC. The earlier BR19 and RADIANT trials failed to demonstrate statistically significant improvements in either OS or DFS for gefitinib and erlotinib, respectively, compared with placebo in patients with EGFR mutation-unselected NSCLC. Three subsequent phase III trials, ADAURA, CTONG1104, and IMPACT, were conducted in EGFR-mutant NSCLC. IMPACT showed no statistically significant DFS benefit for adjuvant gefitinib, and although CTONG1104 did report improved DFS for gefitinib (HR = 0.56,

conclusionAdjuvant osimertinib used alone or following platinum-based chemotherapy is now recommended in patients with stage II-IIIA EGFR-mutated NSCLC.

Indexed as

adjuvant therapyEGFR-positiveNSCLCresected diseasetargeted therapy

Identifiers

PMID34804219
PMCPMC8600554
OpenAlexW3211652415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.